A new era in the management of type 2 diabetes: is cardioprotection at long last a reality!
The EMPA-REG OUTCOME and the LEADER trials have revealed a new era in the management of type 2 diabetes. The SGLT2 inhibitor empagliflozin demonstrated a lower rate of the primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke compared to placebo. Liraglutide, a GLP-1 analogue, succeeded to demonstrate reduction on a composite outcome including first occurrence of cardiovascular death, nonfatal myocardial infarction or non-fatal stroke. These two medications act through different mechanisms and has consequently shown different patterns of cardiovascular benefit.
Source: International Journal of Cardiology - Category: Cardiology Authors: Xavier Rossello, Derek M. Yellon Tags: Editorial Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Heart Attack | Jardiance | SGLT2 Inhibitors | Stroke | Victoza